VRTX — Vertex PharmaceuticalsFREE
Price
$458.99
previous close
Median target
$548
across current calls
Implied return
+19.4%
median target vs. price
Coverage
26 analysts · 31 calls
current predictions
Consensus
24/7/0+24 net
Buy / Hold / Sell
Current analyst calls on VRTX
Sorted by implied return. Each row is one analyst's live rating and price target.
| Analyst | Score | Rank | Succ% | Ret% | Firm | Call | Target | Impl. return | Updated |
|---|---|---|---|---|---|---|---|---|---|
| Terence Flynn | – | – | – | Morgan Stanley | Buy | $616 | +34.2% | May 5, 2026 | |
| Eliana Merle | – | – | – | Barclays | Buy | $615 | +34.0% | May 6, 2026 | |
| Jay Olson | – | – | – | Oppenheimer | Buy | $600 | +30.7% | Mar 10, 2026 | |
| Jay Olson | – | – | – | Oppenheimer | Buy | $600 | +30.7% | May 5, 2026 | |
| Carter Gould | – | – | – | Cantor Fitzgerald | Buy | $590 | +28.5% | Feb 13, 2026 | |
| Akash Tewari | – | – | – | Jefferies | Buy | $580 | +26.4% | Mar 10, 2026 | |
| Naz Rahman | – | – | – | Maxim Group | Buy | $575 | +25.3% | Mar 18, 2026 | |
| Naz Rahman | – | – | – | Maxim Group | Buy | $575 | +25.3% | May 6, 2026 | |
| William Pickering | – | – | – | Bernstein | Buy | $572 | +24.6% | May 5, 2026 | |
| Greg Harrison | – | – | – | Scotiabank | Hold | $558 | +21.6% | Feb 13, 2026 | |
| Louise Chen | – | – | – | Scotiabank | Buy | $558 | +21.6% | May 5, 2026 | |
| Andrew Fein | – | – | – | HC Wainwright & Co. | Buy | $550 | +19.8% | Jun 23, 2025 | |
| Jasper Hellweg | – | – | – | Argus Research | Buy | $550 | +19.8% | Jun 17, 2024 | |
| Mohit Bansal | – | – | – | Wells Fargo | Buy | $550 | +19.8% | May 5, 2026 | |
| Andy Chen | – | – | – | Wolfe Research | Buy | $548 | +19.4% | Jan 6, 2026 | |
| Brian Abrahams | – | – | – | RBC Capital | Buy | $543 | +18.3% | May 5, 2026 | |
| Evan Seigerman | – | – | – | BMO Capital | Buy | $530 | +15.5% | Aug 5, 2025 | |
| Liisa Bayko | – | – | – | Evercore ISI Group | Buy | $530 | +15.5% | Jan 23, 2026 | |
| David Risinger | – | – | – | Leerink Partners | Buy | $525 | +14.4% | Dec 29, 2025 | |
| Joon Lee | – | – | – | Truist Securities | Buy | $525 | +14.4% | Mar 11, 2026 | |
| Liisa Bayko | – | – | – | Evercore ISI Group | Buy | $510 | +11.1% | May 20, 2025 | |
| Phil Nadeau | – | – | – | TD Cowen | Buy | $500 | +8.9% | Jul 23, 2024 | |
| Carter Gould | – | – | – | Cantor Fitzgerald | Buy | $485 | +5.7% | Aug 5, 2025 | |
| Olivia Brayer | – | – | – | Cantor Fitzgerald | Buy | $480 | +4.6% | Feb 11, 2025 | |
| Paul Matteis | – | – | – | Stifel | Hold | $466 | +1.5% | Feb 13, 2026 | |
| Greg Harrison | – | – | – | Scotiabank | Hold | $438 | -4.6% | Aug 5, 2025 | |
| Whitney Ijem | – | – | – | Canaccord Genuity | Hold | $436 | -5.0% | May 5, 2026 | |
| Gena Wang | – | – | – | Barclays | Hold | $414 | -9.8% | Nov 4, 2025 | |
| Do Kim | – | – | – | Piper Sandler | Hold | $296 | -35.5% | Feb 7, 2023 | |
| Hartaj Singh | – | – | – | Oppenheimer | Hold | – | – | Dec 19, 2024 | |
| Robyn Karnauskas | – | – | – | Truist Securities | Buy | – | – | Apr 5, 2024 |
Analyst track records are Premium — unlock every analyst's score, rank and success rate.
Implied return = price target ÷ yesterday's close − 1: the move the stock would make if the analyst's target were hit. These are forward-looking predictions, not realized returns. Only reliable-basis calls are included; the consensus figures above are computed from the calls in this table.